Nanjing Well Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Nanjing Well Pharmaceutical Co Ltd working capital to net assets ratio. Nanjing Well Pharmaceutical Co Ltd (603351) has a Working Capital to Net Assets ratio of 14.6% as of March 2026. Working capital of CN¥268.77 Million (current assets of CN¥959.95 Million minus current liabilities of CN¥691.18 Million) is measured against net assets of CN¥1.84 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Nanjing Well Pharmaceutical Co Ltd's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Nanjing Well Pharmaceutical Co Ltd (2014–2025)
Working capital to net assets ratio of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. This chart shows how Nanjing Well Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of March 2026, the ratio stands at 14.6%, reflecting working capital of CN¥268.77 Million against net assets of CN¥1.84 Billion CNY. See 603351 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Nanjing Well Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2014–2025)
Nanjing Well Pharmaceutical Co Ltd working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Nanjing Well Pharmaceutical Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 11.7% | CN¥210.49 Million | CN¥1.80 Billion | CN¥906.15 Million | CN¥695.66 Million | ▲ +4.6 pp |
| 2024 | 7.1% | CN¥121.30 Million | CN¥1.71 Billion | CN¥717.21 Million | CN¥595.90 Million | ▲ +4.5 pp |
| 2023 | 2.6% | CN¥41.67 Million | CN¥1.59 Billion | CN¥599.42 Million | CN¥557.75 Million | ▲ +10.0 pp |
| 2022 | -7.4% | CN¥-109.74 Million | CN¥1.48 Billion | CN¥470.29 Million | CN¥580.02 Million | ▼ -10.4 pp |
| 2021 | 3.0% | CN¥42.00 Million | CN¥1.39 Billion | CN¥464.69 Million | CN¥422.70 Million | ▼ -11.8 pp |
| 2020 | 14.8% | CN¥192.92 Million | CN¥1.30 Billion | CN¥500.55 Million | CN¥307.63 Million | ▼ -35.5 pp |
| 2019 | 50.3% | CN¥624.31 Million | CN¥1.24 Billion | CN¥823.30 Million | CN¥198.98 Million | ▲ +27.9 pp |
| 2018 | 22.4% | CN¥137.61 Million | CN¥614.61 Million | CN¥318.25 Million | CN¥180.65 Million | ▼ -4.4 pp |
| 2017 | 26.8% | CN¥142.99 Million | CN¥532.80 Million | CN¥319.39 Million | CN¥176.40 Million | ▲ +1.9 pp |
| 2016 | 24.9% | CN¥110.71 Million | CN¥443.99 Million | CN¥256.65 Million | CN¥145.94 Million | ▲ +20.4 pp |
| 2015 | 4.5% | CN¥13.33 Million | CN¥294.49 Million | CN¥205.73 Million | CN¥192.40 Million | ▲ +0.9 pp |
| 2014 | 3.7% | CN¥8.83 Million | CN¥240.35 Million | CN¥187.64 Million | CN¥178.81 Million | — |